283 related articles for article (PubMed ID: 24055694)
41. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome.
Worthington JE; Martin S; Al-Husseini DM; Dyer PA; Johnson RW
Transplantation; 2003 Apr; 75(7):1034-40. PubMed ID: 12698094
[TBL] [Abstract][Full Text] [Related]
42. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival.
Langan LL; Park LP; Hughes TL; Irish A; Luxton G; Witt CS; Christiansen FT
Am J Transplant; 2007 Apr; 7(4):847-56. PubMed ID: 17391128
[TBL] [Abstract][Full Text] [Related]
43. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report.
Süsal C; Döhler B; Opelz G
Hum Immunol; 2009 Aug; 70(8):569-73. PubMed ID: 19375472
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of immune status of kidney transplant recipients by combined HLA-G5 and sCD30].
JIN ZK; TIAN PX; XUE WJ; DING XM; PAN XM; DING CG; JIA LN; GE GQ; HAO JJ
Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(36):2528-31. PubMed ID: 21092456
[TBL] [Abstract][Full Text] [Related]
45. sCD30, interleukin-1beta-converting enzyme and anti-Annexin V autoantibodies concentrations in heart transplant recipients.
Zeglen S; Zakliczyński M; Nozyński J; Rogala B; Zembala M
Transpl Immunol; 2006 Nov; 16(3-4):227-31. PubMed ID: 17138058
[TBL] [Abstract][Full Text] [Related]
46. Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation.
Grenzi PC; Campos ÉF; Silva HT; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-DeLima M
Transpl Immunol; 2015 Mar; 32(2):61-5. PubMed ID: 25698648
[TBL] [Abstract][Full Text] [Related]
47. Advances in pre- and posttransplant immunologic testing in kidney transplantation.
Süsal C; Pelzl S; Simon T; Opelz G
Transplant Proc; 2004; 36(1):29-34. PubMed ID: 15013292
[TBL] [Abstract][Full Text] [Related]
48. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
[TBL] [Abstract][Full Text] [Related]
49. Immunological monitoring of posttransplant allograft sensitization following living related donor renal transplantation.
Panigrahi A; Deka R; Bhowmik D; Tiwari SC; Mehra NK
Transplant Proc; 2004 Jun; 36(5):1336-9. PubMed ID: 15251326
[TBL] [Abstract][Full Text] [Related]
50. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
51. Long-term post transplant alloantibody monitoring: a single center experience.
Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A
Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
[TBL] [Abstract][Full Text] [Related]
52. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
[TBL] [Abstract][Full Text] [Related]
53. Dynamics of anti-human leukocyte antigen antibodies after renal transplantation and their impact on graft outcome.
de Souza PS; David-Neto E; Panajotopolous N; Agena F; Rodrigues H; Ronda C; David DR; Kalil J; Nahas WC; de Castro MC
Clin Transplant; 2014 Nov; 28(11):1234-43. PubMed ID: 25142061
[TBL] [Abstract][Full Text] [Related]
54. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients.
Xydas S; Yang JK; Burke EM; Chen JM; Addonizio LJ; Mital SR; Itescu S; Hsu DT; Lamour JM
J Heart Lung Transplant; 2005 Sep; 24(9):1289-96. PubMed ID: 16143247
[TBL] [Abstract][Full Text] [Related]
55. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation.
Le Bas-Bernardet S; Hourmant M; Valentin N; Paitier C; Giral-Classe M; Curry S; Follea G; Soulillou JP; Bignon JD
Transplantation; 2003 Feb; 75(4):477-82. PubMed ID: 12605113
[TBL] [Abstract][Full Text] [Related]
56. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
[TBL] [Abstract][Full Text] [Related]
57. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience.
Mujtaba MA; Fridell JA; Higgins N; Sharfuddin AA; Yaqub MS; Kandula P; Chen J; Mishler DP; Lobashevsky A; Book B; Powelson J; Taber TE
Clin Transplant; 2012; 26(5):E492-9. PubMed ID: 22938159
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of soluble CD30 as an immunologic marker in heart transplant recipients.
Spiridon C; Hunt J; Mack M; Rosenthal J; Anderson A; Eichhorn E; Magee M; Dewey T; Currier M; Nikaein A
Transplant Proc; 2006 Dec; 38(10):3689-91. PubMed ID: 17175368
[TBL] [Abstract][Full Text] [Related]
59. [Influence of pre-transplant serum level of soluble CD30 on the long-term survival rates of kidney transplant recipients and grafts].
Chen JH; Lü R; Chen Y; Wu JY; He Q; Huang HF; Qu LH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(22):1560-3. PubMed ID: 16179119
[TBL] [Abstract][Full Text] [Related]
60. Preceeding the rejection: in search for a comprehensive post-transplant immune monitoring platform.
Israeli M; Yussim A; Mor E; Sredni B; Klein T
Transpl Immunol; 2007 Jul; 18(1):7-12. PubMed ID: 17584596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
